Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ardox-X Technology mouthrinse is an investigational antimicrobial oral rinse developed by ACTA Dental Research B.V. (Academic Centre for Dentistry Amsterdam) in collaboration with NGen Oral Pharma N.V. The formulation utilizes a peroxoborate-based oxygenating agent (peroxyborate) as its active ingredient, which acts through selective oxygenation and oxidation to inhibit the growth of anaerobic and pathogenic oral bacteria. By targeting oral bacterial biofilms, the mouthrinse aims to prevent de novo dental plaque formation and potentially manage periodontal diseases. Clinical studies in the Netherlands have demonstrated that twice-daily use can shift the oral microbial composition toward a less mature and less diverse plaque state, suggesting potential applications in preventive dentistry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ardox-X Technology mouthrinse.